The
International Myeloma Foundation (IMF) has posted a
news article announcing findings presented at the American Society of Clinical Oncology (ASCO) last week indicating that "novel" treatment options such as Revlimid and Velcade have significantly improved patients' survival. In particular:
- Two-year survival has increased to 93% for newly-diagnosed patients. The survival rate for people without myeloma is only three percent higher,
- Velcade has produced a high complete-response (CR) rate, and
- Further improvements are made by using Revlimid and Velcade in sequence or in combination.
The IMF believes that we are coming closer to making myeloma a chronic disease instead of a fatal one.
Stick around, it's getting better and better!
No comments:
Post a Comment